Manya Charette
Cancer Care Ontario
24 Papers
341 Citations
Manya Charette is an academic researcher from Cancer Care Ontario. The author has contributed to research in topics: Randomized controlled trial & Medicine. The author has an hindex of 15, co-authored 19 publications. Previous affiliations of Manya Charette include McMaster University & American Society of Clinical Oncology.
Chat about Author
Papers
American Society of Clinical Oncology Recommendations on Adjuvant Chemotherapy for Stage II Colon Cancer
Al B. Benson,Deborah Schrag,Mark R. Somerfield,Alfred M. Cohen,Alvaro Figueredo,Patrick J. Flynn,Monika K. Krzyzanowska,Jean A. Maroun,Pamela K. McAllister,Eric Van Cutsem,Melissa C. Brouwers,Manya Charette,Daniel G. Haller +12 more
TL;DR: Direct evidence from randomized controlled trials does not support the routine use of adjuvant chemotherapy for patients with stage II colon cancer, and patients and oncologists who accept the relative benefit in stage III disease as adequate indirect evidence of benefit for stage II disease are justified in considering the use ofAdjuvant chemotherapy.
1.4K
Adjuvant Therapy for Stage II Colon Cancer: A Systematic Review From the Cancer Care Ontario Program in Evidence-Based Care’s Gastrointestinal Cancer Disease Site Group
TL;DR: There is preliminary evidence indicating that adjuvant therapy is associated with a disease-free survival benefit for patients with stage II colon cancer, but these benefits are small and not necessarily associated with improved overall survival.
357
Temozolomide for the Treatment of Metastatic Melanoma: A Systematic Review
TL;DR: The review of the available literature suggests that temozolomide demonstrates comparable activity to the current standard treatment, dacarbazine, with the additional benefit of being a convenient oral treatment that penetrates the blood-brain barrier.
142
Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma
TL;DR: No systemic adjuvant therapy was identified that conferred a significant overall survival benefit in patients with high‐risk, resected, primary melanoma, but high‐dose interferon should be considered in the treatment of these patients, because such therapy is associated with a significant improvement in disease‐free survival and a reduction in 2‐year mortality.
135
Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft-tissue sarcoma: a meta-analysis and clinical practice guideline.
TL;DR: Recommendations are made that future randomized clinical trials should compare new regimens, whose activity has been established in single-arm studies, with single-agent doxorubicin, and include quality of life as an outcome measure.